A kinase interacting protein 1 (AKIP1) stimulates physiological growth in cultured cardiomyocytes and attenuates ischemia / reperfusion (I/R) injury in ex vivo perfused hearts. We aimed to determine whether AKIP1 modulates the cardiac response to acute and chronic cardiac stress in vivo.
Introduction
Heart failure constitutes a major public health problem with a lifetime risk of 20-30% to develop this disease. 1, 2 While treatment and survival of heart failure have improved over the past decades, morbidity and mortality for heart failure still exceeds that of most malignancies. 3 Novel therapies are therefore urgently needed. In an attempt to identify novel therapies that contribute to heart failure development, we performed a multilevel genome wide transcription study in several complimentary heart failure models. This analysis revealed marked upregulation of the gene encoding for A Kinase Interacting Protein 1 (AKIP1). 4 AKIP1 was originally identified as Breast Cancer Associated gene 3 (BCA3), which is upregulated in several different types of cancer. In cancer cells, AKIP1 has been shown to modulate NF-kB and PKA activity, 5, 6 which results in the induction of apoptosis and the reduction in tumour progression. [7] [8] [9] [10] In contrast, some investigators have reported that AKIP1 rather stimulates neovascularisation and tumor growth. 11, 12 This apparent discrepancy suggests that the role of AKIP1 may vary in different cell types and clinical situations.
Gain-and loss of function experiments with AKIP1 in cultured cardiomyocytes have revealed that AKIP1 promotes a physiological type of hypertrophy by activating AKT. 13 AKIP1 was also found to promote mitochondrial respiration and improve mitochondrial coupling efficiency while simultaneously attenuating mitochondrial ROS emissions. 14 Additional evidence for the involvement of AKIP1 in mitochondrial physiology comes from a recent study which showed that AKIP1-gene transfer protects cultured cardiomyocytes and isolated perfused hearts from ischemia / reperfusion (I/R). 15 Together these findings suggest that AKIP1 may have a beneficial effect on both acute and chronic cardiac insults. It also suggests that interventions that target AKIP1 could offer a viable strategy to prevent cardiac dysfunction in various cardiac diseases. Accordingly, we hypothesized that overexpression of AKIP1 would improve cardiac resilience to acute and chronic cardiac stress. To investigate this hypothesis, we generated a mouse line with cardiomyocyte-specific overexpression of AKIP1.
Methods

Animal models Generation of transgenic mice
To create mice with cardiac-specific overexpression of AKIP1, a construct was created which consisted of the mouse AKIP1 sequence (NM_020616.1) inserted between an α-MHC promoter and a polyA tail ( Figure 1A) . This construct was used for pronuclear injection in FVB embryos to create transgenic mice. These mice were created by the UMCG mouse transgenic facility in collaboration with Mayo Clinics (Minnesota, USA) and backcrossed into a C57Bl6/J background, as described before. 16 Male mice were used for all experiments. AKIP1-transgenic mice (AKIP1-TG) and wild type (WT) littermates were phenotyped 4 and 12 months of age with magnetic resonance imaging (MRI), echo and histological staining as described below. Mice between the ages of 8-12 weeks were used for all the experiments. Surgery, imaging and euthanasia were performed under 2% isoflurane anaesthesia with heart rate, temperature and breathing monitoring. The animal experiments were approved by the Animal Ethics Committee from the University of Groningen (DEC6237) and performed in adherence to the guidelines from Directive 2010/63/EU of the European Parliament.
Heart failure models
We used 2 distinct models for chronic heart failure; first, transverse aortic constriction (TAC) was performed with a 7-0 nylon suture between the carotid arteries around a 27.5G needle, as described. 17 Second, post-myocardial infarction (MI) heart failure was achieved through a permanent ligation of the left coronary artery with a premilene 6-0 suture. Cardiac function was assessed with echocardiography or MRI at consecutive time points. Finally, intracardiac pressure measurements were obtained before sacrifice, as described. 18 Myocardial I/R injury In vivo I/R injury was performed by 45min ligation of the left coronary artery, followed by 24 hours of reperfusion. After 24h, the coronary artery was religated, followed by abdominal vein injection with Evans Blue (2% in 0.9% NaCl) to delineate the area at risk. The hearts were immediately excised, cut in 1 mm thick slices and stained in 1% Triphenyltetrazoliumchloride for 15 minutes at 37 o C. Slices were fixed in 4% paraformaldehyde and scanned at 4800 dpi (Cannon 900F). Area at risk and infarct size were quantified using ImageJ.
Figure 1
Changes in cardiac structure and function induced by AKIP1 overexpression. (A) Schematic picture of the transgenic construct that was inserted in mice. (B) Western blot of AKIP1 expression in hearts of AKIP1-transgenic (AKIP1) and wild-type (WT) mice. GAPDH was used as a loading control. Samples were run on the same gel and pictures were taken from the same blot and same exposure time. For quantitative measurements, see Supplementary material online, Figure S1A . (C) Cardiac function parameters as determined by magnetic resonance imaging at 4 and 12 months and representative enddiastolic images. Shown are Left Ventricular Ejection Fraction, LVEF; Left Ventricular End-Diastolic Volume, LVEDV and Left Ventricular End-diastolic Mass, LVEDmass. N=7-8 animals for the groups at 4 months and N=4 animals for both groups at 12 months. Error bars represent mean ± SE. Statistical testing was performed with a Student t test. AKIP1-TG and WT were compared at 4 months and a separate comparison was made at 12 months; n.s., not significant. (D) Cardiomyocyte size was slightly smaller in AKIP1-TG mice compared to WT mice at age 4 months. Shown are representative images of wheat germ agglutinin staining and measurements of cardiomyocyte cross-sectional diameter. N=22 animals for WT and N=24 animals for AKIP1-TG. All values are expressed as mean ± SE. Statistical analysis was performed by student t test; **, p< 0.01. 
Assessment of cardiac function and hemodynamics
Hemodynamic function parameters were obtained under isoflurane anaesthesia with echocardiography, MRI and intracardiac pressure measurements. MRI was performed in a 9.4T 400 MR system (Bruker BioSpin, Ellingen, Germany) as previously described. 19 ParaVision 4.0 and IntraGate software (Bruker BioSpin GmBH, Germany) were used for cine-MR acquisition and reconstruction. Shortaxis slices were obtained to determine the end-systolic and end-diastolic dimensions of the left ventricle (QMass, version MR 6.1.5, Medis Medical Imaging Systems, The Netherlands). Aortic and intra-cardiac pressures were measured with a Millar catheter (Micro-Tip 1.4 French; SPR,-839, Millar instruments, Houston, TX, USA), as described. 18 Data were analysed with LabChart 7 software (Version 7.2 ADinstruments, New Zealand).
Histology
Midpapillary slices of the left ventricle were fixated for 24h in 4% paraformaldehyde. Tissues were dehydrated using an automated system (Leica, TP 1020, Germany) and embedded in paraffin. Sections of 4 µm were stained with Masson-Trichrome staining to determine fibrosis. Infarct size after MI was measured from a midpapillary slice as the percentage of the epicardial contour with transmural infarction. Apoptosis and capillary density were determined with antibodies against cleaved-caspase-3 (Cell Signalling, USA) and CD31 (Dianova, Germany) respectively with subsequent incubation of IgG secondary antibodies coupled to peroxidase followed by diaminobenzidinestaining. Cardiomyocyte diameter was determined with staining for wheat germ agglutinin (Sigma, USA). Quantification was performed with ImageJ or Aperio ImageScope v11.
Subcellular fractionation
Fresh ventricular tissue was minced and subsequently homogenised in homogenization buffer (70 mM sucrose, 190 mM Mannitol, 20 mM HEPES, 0.2 mM EDTA, proteaseinhibitor-cocktail (Roche), phosphatase inhibitor cocktail (Sigma), 1 µM sodiumorthovanadate, 1 mM PMSF) with a glass dounce mortar. The homogenate was centrifuged at increasing speed to separate enriched subcellular fractions. Protein concentration was measured and processed for western blot.
Mitochondrial swelling
Cardiac mitochondria were freshly isolated from AKIP1-TG and WT littermates with a polytron 3000, speed 3 in MSHE buffer (70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM EGTA, 0.5% fatty-acid-free BSA). The solution was centrifuged at 500 G for 10 minutes at 4 o C to remove nuclei and cell debris. The supernatant was spun at 6000 G for 10 minutes at 4 o C to pellet the mitochondria. The pellet was washed again and diluted to 300 µg/ml in swelling buffer (125 mM KCl, 5 mM KH2PO4, 20 mM HEPES, 5 mM glutamate, 5 mM malate) and pipeted in a clear-bottom microtiter-plate. Absorbance was measured at 540 nm on 37 o C. After initiation, Ca2+ (150 µM) was added.
Co-immunoprecipitation
We performed a co-immunoprecipitation study as previously described. 20 A rabbit anti mouse AKIP1 antibody and protein lysates from AKIP1-TG and WT mice were used. After co-immunoprecipitation, samples were processed for western blot.
PKA activity assay
PKA activity was measured in mitochondria isolated from the area at risk, using a colorimetric assay (MESACUP Protein Kinase Assay, MBL CO., Ltd, Nagoya, Japan). The assay was performed according to the manufacturers protocol for the specific measurement of PKA-activity.
NF-κB activity assay
NF-κB activity was measured in nuclear enriched lysates with an enzymelinked NF-κB immunosorbent assay method (TransAM NF-κB, Active Motif, Carlsbad, CA, United States) according to the manufacturers protocol.
Culturing of primary cardiomyocytes and cell size measurement
Neonatal rat ventricular cardiomyocytes (NRVCs) were isolated and cultured as previously described. 13 24 hours after isolation, NRVCs were infected with adenovirus virus overnight. After subsequent starvation in serum-free conditions for 48h, protein was isolated for western blot analysis or cells were fixed in paraformaldehyde for staining and cell size measurement, as previously described. 13
Western blot and antibodies/reagents
Western blot was performed as described previously. 13 An AKIP1 antibody was made in our lab as described previously. 13 Antibodies for PARP, COX-IV, αactinin, wheat germ agglutinin, α-tubulin (SIGMA), SERCA2ATPase (ABCAM), anti-phosphorylated-Akt Ser473 , anti-total-Akt (cell signaling) and GAPDH (Fitzgerald) were bought commercially.
Statistics
Values are displayed as mean ± standard error of the mean. Comparisons between 2 groups were made with Student t test or a Logrank test where applicable. Whenever the experimental design compared the response of AKIP1-TG and WT mice to an intervention, we first compared the effect of the intervention using a two-way ANNOVA. If the two-way ANNOVA revealed a significant difference between the combined intervention groups, we compared all 4 groups using the post-hoc Tukey test. A p-value <0.05 was considered significant.
Results
Baseline phenotyping of AKIP1-TG mice
To investigate the role of AKIP1 in cardiomyocytes, mice that express AKIP1 under control of the α-MHC promoter were generated (Cloning strategy is depicted in Figure 1A ). Overexpression of AKIP1 was cardiac specific as confirmed by analysis of mRNA and protein levels ( Figure 1B , and Suppl. mat. online, Figure S1A ). AKIP1-TG mice were born in normal mendelian frequencies and were phenotypically normal. They displayed normal behaviour and reproductive capacity was not affected. In contrast to in vitro studies 13 , AKIP1 overexpression did not induce cardiac hypertrophy. In fact, cardiomyocyte cross-sectional diameter was marginally smaller in AKIP1-TG mice compared to WT mice, but overall left ventricular (LV) mass was identical ( Figure 1C and D, and Suppl. mat. online, Figure S1C ). Furthermore, AKIP1-TG mice displayed normal cardiac function and LV dimensions throughout the course of 12 months ( Figure 1C , and Supplementary material online, Figure S1B ). Levels of AKIP1 expression were stable throughout the course of one year, and chronic cardiac stress did not affect AKIP1 expression levels (Suppl. mat. online, Figure  S1E ). The 40-fold increase in cardiac AKIP1 protein expression that was achieved in our AKIP1-TG mice may be considered to be relatively high. To exclude that the lack of spontaneous hypertrophy in vivo could be explained by an off-target effects resulting from the level of protein overexpression we studied the effect of multiple levels of AKIP1 overexpression in NRVCs. Interestingly, increasing AKIP1 protein expression levels up to 600-fold, resulted in a continuous dose-dependent increase in cardiomyocyte hypertrophy in NRVCs (Suppl. mat. online, Figure S1D ). Accordingly, it is unlikely that the the level of AKIP1 protein expression is sufficient to explain the the absence of AKIP1-induced cardiac hypertrophy in vivo. To evaluate whether AKIP1 modulates hypertrophy and heart failure development, AKIP1-TG and WT mice were subjected to 2 clinically relevant models of heart failure development. First, the mice were subjected to TAC and followed up for a total duration of 7 weeks. The degree of LV hypertrophy that developed after TAC was comparable between WT and AKIP1-TG mice, as determined by LV mass measured with MRI, LV weight divided by tibia length and cardiomyocyte cross sectional diameter (Figure 2A, 3B and D) . TAC resulted in marked LVdysfunction, but the reductions in LV-ejection fraction and LV-dilatation were similar in AKIP1-TG and WT mice (Figure 2A) . Additionally, invasive measurements of contractility and relaxation were all similar in AKIP1-TG and WT mice ( Figure 2B ). The expression of molecular markers of LV-remodeling and cardiac fibrosis were also comparable between the groups ( Figure 3A and  C) . As the TAC model described above resulted in a relatively mild form of heart failure, we also investigated the role of AKIP1 after permanent proximal LAD ligation. Approximately 60% of the mice survived the entire study duration of 6 weeks. Most deaths occurred within the first week after MI and mortality was similar in AKIP1-TG and WT mice ( Figure 4A ). Total fibrosis in the left ventricular free wall remote from the infarction at 6 weeks after MI was reduced in AKIP1-TG mice ( Figure 5A , left panel) as was infarct size after MI (51 ± 4% vs. 36 ± 4%, p<0.05 in WT and AKIP1-TG mice respectively ( Figure  5A right panel) . Average heart weight at 6 weeks was comparable between groups, but cardiomyocyte cross-sectional diameter after MI or sham surgery was significantly lower in AKIP1-TG animals compared to WT mice ( Figure 4B The degree of LV dysfunction that developed after MI was more severe than in the TAC-model, but again cardiac function parameters were comparable between AKIP1-TG and WT mice ( Figure 4B) . The cardiac expression of markers for heart failure severity, ANP and BNP, were comparable between AKIP1-TG and WT mice after MI ( Figure 5C ). Furthermore, cardiac microvasculature was also comparable between the groups (Supplementary material online, Figure S2 ).
AKIP1 reduces infarct size after I/R and reduces mitochondrial swelling
Sastri et al. previously showed that AKIP1-levels are increased in cultured cardiomyocytes upon oxidant stress and that AKIP1 exerts cardioprotective effects during in vitro and ex vivo myocardial ischemia. 15 To test whether these effects translate into protection in vivo, AKIP1-TG and WT littermates were subjected to cardiac I/R injury. Survival after 24h was 100% in both groups. While the area at risk was comparable between the groups, AKIP1-TG animals had a 2-fold reduction in myocardial infarct size ( Figure 6A) accompanied by a significant reduction in apoptosis in the area at risk ( Figure 6B ). Previous studies have indicated that AKIP1 functions as a signalling modulator affecting, among others, the activity of NF-kB, PKA and AKT. 5, 6, 13 Furthermore, AKIP1 was shown to directly bind to NF-kB and PKA in various malignant cell lines. 5 However, the reduction in I/R injury in AKIP1-TG mice could not be explained by modulation of NF-kB, PKA and AKT that are known to influence the degree of I/R injury ( Figure 6C,D, 7B , Supplementary material online Figure S3A, B ). In addition, AKIP1 did not immunoprecipitate with NF-kB, PKA or AKT in lysates from WT and AKIP1-TG animals subjected to I/R ( Figure 7A) . Therefore, the reduction in I/R damage cannot be explained by activation of these previously indentified targets of AKIP1 21, 22 Previously it was shown that AKIP1 is expressed in mitochondria and that overexpression of AKIP1 improved mitochondrial function. 14, 15 First we performed a subcellular fraction study in AKIP1-TG and WT mice, which confirmed that AKIP1 is enriched in mitochondria (Supplementary material online, Figure S3C ). Because Sastri et al. suggested that AKIP1 activated mitochondrial PKA, 15 we evaluated PKA activity in the mitochondrial fraction after I/R. Similar to what was observed in the whole cell lysate, mitochondrial PKA activity after I/R was also not affected by AKIP1 overexpression ( Figure 7B ). Recent evidence indicates that a large component of I/R damage is mediated through the activation of the mitochondrial permeability transition pore (MPT pore). 22 Mitochondrial ATP-synthase has been recognised as a key component of the MPT pore. 23 It has been shown that AKIP1 influences the phosphorylation of ATP synthase by PKA, but a direct interaction between AKIP1 and ATP-synthase has not been established. In our co-immunoprecipitation analysis, we discovered that AKIP1 coimmunoprecipitated with ATP-synthase ( Figure 7A ), suggesting that the protective effects of AKIP1 result from the attenuation of MPT pore formation. To test this hypothesis, we performed a calcium-induced swelling assay in isolated cardiac mitochondria. Interestingly, the mitochondria isolated from AKIP1-TG mice displayed a significant reduction in calcium induced swelling which is indicative of attenuated MPT pore formation ( Figure 7C ). 
Discussion
We sought to determine the role of AKIP1 in cardiac remodeling because in vitro evidence suggested that AKIP1 is critically involved in the development of cardiomyocyte hypertrophy and the cardiac response to oxidative stress. 4, [13] [14] [15] By generating AKIP1-TG mice, we were able to determine whether these in vitro findings could translate into relevant protective mechanisms in vivo for the first time. In contrast to previous reports, however, a stable 40-fold increase in cardiac AKIP1-protein expression did not influence cardiac structure and function up to the age of 1 year. In addition, AKIP1 overexpression did not modulate reactive hypertrophy or LV remodeling induced by pressure overload or chronic MI. AKIP1-overexpression did, however, attenuate myocardial infarct formation in response to permanent and transient myocardial ischemia and reduced myocardial apoptosis. In contrast to our expectations, the reduction of I/R injury by AKIP1 could not be explained by an interaction with the signaling molecules NF-kB, PKA or AKT. Instead, we found that AKIP1 was enriched in cardiac mitochondria, where it co-immunoprecipitated with a key component of the MPT pore, ATP synthase. AKIP1 also prevented calciuminduced mitochondrial swelling, which is considered to be indicative of reduced MPT pore formation. Together, our findings indicate that cardiomyocyte-specific overexpression of AKIP1 does not influence heart failure development but does offer protection during myocardial I/R injury. Previous findings in cultured cardiomyocytes and other cell types suggested that AKIP1 could be a key mediator of the cardiac response to acute and chronic stress. [11] [12] [13] 15 However, our in vivo data do not fully confirm this hypothesis as AKIP1 overexpression did not induce cardiac hypertrophy, nor Figure 6 Overexpression of AKIP1 reduces myocardial ischemia / reperfusion injury. (A) Infarct formation after 45 minutes of ischemia and 24 hours of reperfusion in hearts of AKIP1-transgenic (AKIP1) and wild-type (WT) mice. Shown are Area at risk (AAR), infarct size relative to the AAR and representative images of the Evans Bleu / TTC staining. N=10 animals for both groups; Error bars represent mean ± SE. Statistical testing was performed with Student t test; *, p<0.05; n.s., not significant. (B) Apoptosis after reperfusion. Shown are representative images of Caspase-3 staining in the area at risk 24 hours after reperfusion. N=8 animals for wild type (WT) and N=5 animals for AKIP1-transgenic groups; Error bars represent mean ± SE. Statistical testing was performed with Student t test; *, p<0.05. (C) Shown is the relative nuclear activity of NF-kB of AKIP1-transgenic and WT mice after reperfusion for 30 minutes. N=5-8 animals per group. Error bars represent mean ± SE. Statistical testing was performed by twoway ANOVA, followed by a post-hoc Tukey to compare the differences between all groups; n.s., not significant. (D) Myocardial AKT-phosphorylation after ischemia / reperfusion. Shown are densitometric analysis and representative blots. Samples were run on the same gel and pictures were taken from the same blot and same exposure time. N=10-12 animals per group. Error bars represent mean ± SE. Statistical testing was performed by two-way ANOVA, followed by a post-hoc Tukey to compare the differences between all groups; *, p<0.05; n.s. not significant. did it influence cardiac remodelling or cardiac dysfunction upon chronic cardiac stress. In fact, where AKIP1 overexpression induced hypertrophic growth in NRVCs, AKIP1-TG mice displayed a modest reduction of cardiomyocyte hypertrophy. There are numerous potential explanations for this apparent discrepancy. First, the in vitro studies were done with immature NRVCs. In addition to the non-physiological influence of the isolation procedure and culture conditions, these cells are harvested during a postnatal period where the heart and circulatory system undergoes significant transitions that influence the cardiac response to stress. This is exemplified by the response to ischemia / reperfusion injury. 24 Second, the development of cardiac hypertrophy is strongly influenced by the activation neurohormonal systems and several other interactions between cardiomyocytes and other cell types, such as cardiac fibroblasts and endothelial cells. These interactions are lost in vitro. Third, the type of hypertrophy induced by AKIP1 in cultured cardiomyocytes did resemble physiological cardiac hypertrophy rather than the "pathological" hypertrophy that typically develops during heart disease. 13 Since we only used models of cardiac disease, we cannot exclude the possibility that AKIP1 is a specific mediator of physiological hypertrophy. Future studies are required to specifically address the role of AIKP1 during exercise. Our I/R studies did confirm previous work by Sastri et al. who reported that AKIP1 was upregulated in cardiomyocytes in response to oxidative stress and that AKIP1 attenuated cardiomyocyte apoptosis in vitro. 15 Furthermore, they also showed that acute adenoviral gene-transfer of AKIP1 attenuated ex vivo I/R injury through various mitoprotective mechanisms including phosphorylation of the alpha subunit of ATP synthase. 15 ATP synthase is the key component of the MPT pore, which is a critical mediator of myocardial damage after I/R. 22, 23 Our studies also showed that AKIP1 is enriched in mitochondria and that it interacts with ATP-synthase. Furthermore, we now show for the first time that AKIP1 attenuates in vivo I/R injury and reduces mitochondrial MPT pore formation as evidenced by reduced calcium induced mitochondrial swelling. Together these findings strongly suggest that the cardioprotective effects of AKIP1 are mediated by an interaction with ATP synthase that results in the stabilization of the MPT pore. It therefore, appears that AKIP1 is primarily involved in the regulation of acute mitochondrial stressresponses in cardiomyocytes. Of note, the changes in mitochondrial respiration observed in NRVCs, 14 could also result from modulation of ATP synthase.
The major difference between our findings and previous work using in vitro and ex vivo systems is the fact that AKIP1 did not co-immunoprecipitate with or modulate the signaling molecules NF-kB, PKA or AKT. As described above, this could be explained by differences between (immature) cell culture systems and adult animals. Another major difference is that previous studies used acute global gene transfer using adenoviral vectors, whereas our AKIP1-TG mice displayed stable constitutional and cardiomyocyte-specific overexpression of AKIP1. One can envision that the different activation of signaling pathways could result from these methodological differences or from the expression of AKIP1 in other cardiac cells. As our model is more stable and allows us to study the specific effect of AKIP1 in cardiomyocytes, we consider our findings more robust. Finally, the protective effects of AKIP1 on cardiac tissue and cardiomyocytes is in contrast to studies in malignant cell lines where AKIP1 stimulated apoptosis. 9, 10 This apparent discrepancy could be explained by the fact that the cytotoxic stressors used in experiments with malignant cells are in many ways very different from I/R injury. Additionally, the metabolic stress in malignant cells is predominantly caused by proliferation, whereas cardiomyocytes are terminally differentiated. Several mechanisms are responsible for the ultimate development of reperfusion injury. 25, 26 Many promising therapeutics are currently under development that target the production of reactive oxygen species (ROS) or specifically inhibit early MPT pore opening. 25, 26 Mitochondrial swelling and MPT pore formation can lead to the activation of the apoptotic cascade and also activate the process of necroptosis. 21, 22 Our finding that AKIP1 attenuates mitochondrial MPT pore formation suggests that interventions that modulate AKIP1 could be protective when given to patients with an acute MI. The apparent discrepancy between the effect of AKIP1 overexpression during acute and chronic cardiac stress could be explained by the fact that the MPT pore formation has a very distinct and critical physiologic role in the regulation of mitochondrial calcium handling and metabolism. 27 Indeed, our findings are in line with studies using the specific MPT pore inhibitor cyclosporine A, which failed to influence cardiac remodelling after TAC but does offer potent protection during MI. 28 
Conclusion
In contrast to in vitro studies, AKIP1 overexpression does not attenuate cardiac remodeling in response to chronic cardiac stress. AKIP1 does reduce myocardial I/R injury through stabilization of the MPT pore. These findings suggest that AKIP1 deserves further investigation as a putative treatment target for cardioprotection from I/R injury during acute myocardial infarction. Capillary density 6 weeks after myocardial infarction as determined with CD-31 staining. Shown are numbers of capillaries per mm 2 and representative images of CD-31 staining in hearts of AKIP1-transgenic (AKIP1) and wildtype (WT) mice. N=10-11 animals per group. Error bars represent mean ± SE. Statistical testing was performed by two-way ANOVA, followed by a post-hoc Tukey to compare the differences between all groups; ***, p<0.001; n.s., not significant. 
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